CD274 and neoplasm: However, oncogenic driver mutations are only present in 15–20% of NSCLC patients and PD-L1 tumor proportion score (TPS) ≥ 50% in 28% of advanced NSCLC, thereby limiting the use of these novel treatment strategies [29,30].